×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Skip to main content
Tags: Coronavirus | Financial Markets | Money | Vaccines | Food and Drug Administration | COVID-19 vaccination | Merck

FDA to Review Merck's COVID-19 Vaxx: Bloomberg

Merck
(AP)

Thursday, 14 October 2021 01:06 PM

The U.S. Food and Drug Administration will send drugmaker Merck & Co's experimental COVID-19 antiviral drug to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.

The advisory committee will weigh in on molnupiravir's safety concerns, which have been raised by some experts, before the FDA makes a decision on authorization of the drug, the report said.

Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.

Merck, Pfizer, Roche -- All in Race for a Pill

Pfizer Inc and Swiss drugmaker Roche Holding AG are also racing to develop an easy-to-administer antiviral pill for COVID-19.

Merck is developing molnupiravir in partnership with U.S.-based Ridgeback Biotherapeutics.

In early October, data showed Merck's drug could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, pummeling shares of coronavirus vaccine makers.

The FDA and Merck did not immediately respond to Reuters' requests for comment.

© 2021 Thomson/Reuters. All rights reserved.


StreetTalk
The U.S. Food and Drug Administration (FDA) will send drug maker Merck & Co.'s experimental COVID-19 antiviral drug to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.
Food and Drug Administration, COVID-19 vaccination, Merck, Pfizer, Roche
186
2021-06-14
Thursday, 14 October 2021 01:06 PM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved